WHY most (but perhaps not all) DMARDs work equally well

Detalhes bibliográficos
Autor(a) principal: Landewé, Robert B M
Data de Publicação: 2024
Outros Autores: Sepriano, Alexandre, Bergstra, Sytske Anne
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/162912
Resumo: Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
id RCAP_807da10adf44d4f3fc0f909c536af93f
oai_identifier_str oai:run.unl.pt:10362/162912
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling WHY most (but perhaps not all) DMARDs work equally wellRheumatoid arthritisDMARDs JAK-inhibitorsRandomized clinical trials Non-specific treatment effectsCopyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.Biological- or targeted-synthetic DMARD-responses reported in randomized clinical trials, placebo-controlled or head-to-head, in patients with rheumatoid arthritis, psoriatic arthritis or spondyloarthritis are unbelievably similar, when looking across trials performed in the same disease and applying the same primary outcome measures. The exception to this rule may be the response to Janus-kinase-inhibitors, which seem to work 10 % better in all trials (JAK-bonus) This article provides a potential explanation for this remarkable phenomenon, including an explanation for the JAK-bonus. It seems as if JAK-inhibitors exert some inflammation-independent effects on pain, fatigue and wellbeing, and that drug treatment of rheumatic diseases is more than the inhibition of inflammation alone.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)RUNLandewé, Robert B MSepriano, AlexandreBergstra, Sytske Anne2024-01-31T00:11:53Z2024-012024-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/162912eng0049-0172PURE: 82241025https://doi.org/10.1016/j.semarthrit.2023.152316info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-05-22T18:17:54Zoai:run.unl.pt:10362/162912Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-05-22T18:17:54Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv WHY most (but perhaps not all) DMARDs work equally well
title WHY most (but perhaps not all) DMARDs work equally well
spellingShingle WHY most (but perhaps not all) DMARDs work equally well
Landewé, Robert B M
Rheumatoid arthritis
DMARDs JAK-inhibitors
Randomized clinical trials Non-specific treatment effects
title_short WHY most (but perhaps not all) DMARDs work equally well
title_full WHY most (but perhaps not all) DMARDs work equally well
title_fullStr WHY most (but perhaps not all) DMARDs work equally well
title_full_unstemmed WHY most (but perhaps not all) DMARDs work equally well
title_sort WHY most (but perhaps not all) DMARDs work equally well
author Landewé, Robert B M
author_facet Landewé, Robert B M
Sepriano, Alexandre
Bergstra, Sytske Anne
author_role author
author2 Sepriano, Alexandre
Bergstra, Sytske Anne
author2_role author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
RUN
dc.contributor.author.fl_str_mv Landewé, Robert B M
Sepriano, Alexandre
Bergstra, Sytske Anne
dc.subject.por.fl_str_mv Rheumatoid arthritis
DMARDs JAK-inhibitors
Randomized clinical trials Non-specific treatment effects
topic Rheumatoid arthritis
DMARDs JAK-inhibitors
Randomized clinical trials Non-specific treatment effects
description Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
publishDate 2024
dc.date.none.fl_str_mv 2024-01-31T00:11:53Z
2024-01
2024-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/162912
url http://hdl.handle.net/10362/162912
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 0049-0172
PURE: 82241025
https://doi.org/10.1016/j.semarthrit.2023.152316
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv mluisa.alvim@gmail.com
_version_ 1817545982926127104

Registros relacionados